Akebia Therapeutics AKBA 深 滬
等待開盤 12-16 09:30:00 美东时间
1.61
-0.050
-3.01%
華盛通- 最 高1.68
- 今 開1.68
- 成交量 206.40万股
- 最 低 1.59
- 昨 收 1.66
- 總市值 4.27亿
- 52周最高 4.0787
- 市盈率 靜 --
- 換手率 0.78%
- 52周最低 1.445
- 委 比 -3.61%
- 總股本 2.65亿
- 歷史最高 31.00
- 量 比 0.64
- 振 幅 5.42%
- 歷史最低 0.241
- 每 手 1
- 風險率 0.73%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 最高500美元！MongoDB获18家大行紧急上调目标价；巴克莱下调理想汽车目标价至18美元
今日重点评级关注：B. Riley证券：维持Seabridge Gold"买入"评级，目标价从50美元升至65美元；HC Wainwright & Co.：维持TRX Gold"买入"评级，目标价从1.2美元升至1.4美元
12-03 09:58
BTIG Reiterates Buy on Akebia Therapeutics, Maintains $5 Price Target
BTIG analyst Julian Harrison reiterates Akebia Therapeutics (NASDAQ:AKBA) with a Buy and maintains $5 price target.
12-02 23:45
Cyclerion Receives Milestone Payment from Akebia
Cyclerion Therapeutics ( ($CYCN) ) has issued an update. On December 1, 2025, A...
12-02 06:28
Why Is Small-Cap Q32 Bio Stock Soaring On Monday?
Q32 Bio shares rise after selling ADX-097 to Akebia in a deal worth up to $592 million, boosting cash runway into late 2027.
12-01 22:43
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics granted options to purchase 22,576 shares of its common stock to two newly hired employees on November 28, 2025. The options, priced at $1.58 per share, vest over four years, with 25% vesting after the first year and the remaining 75% vesting quarterly thereafter, contingent on continued employment. The grants align with Nasdaq Listing Rule 5635(c)(4) and include a 10-year term under the company's inducement award program.
12-01 21:05
Market-Moving News for December 1st
QTTB: 97% | Q32 Bio Sells Phase 2 Complement Inhibitor ADX-097 To Akebia Therapeutics For $12M Upfront Payment; Co. Eligible To receive Up To $592M In Milestones As Well As Royalties DYAI: 35% | Dyadic
12-01 20:37
Akebia Therapeutics Establishes Rare Kidney Disease Pipeline With AKB-097 Acquisition From Q32 Bio And Praliciguat Candidate
Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 BioPhase 2 basket trial planned to evaluate complement inhibitor in multiple rare kidney disease indicationsPhase 2 trial
12-01 20:09
Q32 Bio Sells Complement Inhibitor ADX-097
-- Asset sale further enables Company's strategic focus on advancing bempikibart for alopecia areata -- -- $12 million in upfront and guaranteed near-term milestone payments expected to exte...
12-01 20:00
Akebia Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
Akebia Therapeutics, a biopharmaceutical company focused on improving lives affected by kidney disease, announced that its executives will participate in a Fireside Chat at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, at 4:30 PM EST in New York City. A webcast of the presentation will be available on Akebia’s Investor website following the event.
11-24 13:00
Akebia Therapeutics Amends License Agreement with MEDICE
The latest update is out from Akebia Therapeutics ( ($AKBA) ). On November 12, ...
11-17 21:23
